

Dated- 24.01.2025

**BSE LIMITED**

Corporate Relations Department  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai-400001  
Scrip code: 543264

**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Listing Department  
Exchange Plaza, 5<sup>th</sup> Floor, Plot no. C/1  
G Block, Bandra Kurla Complex, Bandra (E)  
Mumbai-400051  
Scrip Code: NURECA

**Subject: Integrated Filing (Financials) for the third quarter and nine months ended December 31, 2024**

Dear Sir/Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financials) for the third quarter and nine months ended December 31, 2024.

This is for your kind information and records please.

Thanking You,

Yours Sincerely,  
For Nureca Limited

(Saurabh Goyal)  
Chairman & Managing Director

**NURECA LIMITED**

Correspondence Office : SCO 6-7-8, 1st Floor Madhya Marg, Sector 9-D, Chandigarh 160009  
Registered Office : 101 Office Number Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,  
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

## A. Financial Results

NURECA LIMITED							
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India							
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com							
Corporate Identification Number: L24304MH2016PLC320868							
(Amount in INR million, unless otherwise stated)							
Statement of Unaudited Standalone Financial Results for the Quarter and Nine months ended 31 December 2024							
Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December 2024 (Unaudited)	30 September 2024 (Unaudited)	31 December 2023 (Unaudited)	31 December 2024 (Unaudited)	31 December 2023 (Unaudited)	31 March 2024 (Audited)
1	Revenue from operations	272.08	323.70	223.74	828.90	749.58	945.21
2	Other income	15.18	32.09	59.21	105.42	118.13	105.64
3	<b>Total income (1+2)</b>	<b>287.26</b>	<b>355.79</b>	<b>282.95</b>	<b>934.32</b>	<b>867.71</b>	<b>1,050.85</b>
4	<b>Expenses</b>						
	Purchase of stock-in-trade	208.97	178.83	104.53	556.11	503.73	631.90
	Changes in inventories of stock-in-trade	(16.51)	50.70	66.11	33.82	18.07	41.56
	Employee benefits expense	36.00	33.91	31.05	103.74	86.57	115.66
	Finance costs	1.41	2.52	1.01	5.21	2.89	4.60
	Depreciation and amortization expense	4.93	5.73	5.62	16.78	16.78	22.42
	Other expenses	90.94	86.81	66.33	238.24	204.94	267.40
	<b>Total expenses</b>	<b>325.74</b>	<b>358.50</b>	<b>274.65</b>	<b>953.90</b>	<b>832.98</b>	<b>1,083.54</b>
5	<b>Profit/(Loss) before income tax (3-4)</b>	<b>(38.48)</b>	<b>(2.71)</b>	<b>8.30</b>	<b>(19.58)</b>	<b>34.73</b>	<b>(32.69)</b>
6	<b>Tax expense</b>						
	- Current tax	(2.88)	5.07	11.72	8.87	13.98	13.52
	- Deferred tax charge/ (credit)	(2.71)	(1.32)	(4.20)	(1.05)	1.03	(21.79)
7	<b>Profit/(Loss) after income tax (5-6)</b>	<b>(32.89)</b>	<b>(6.46)</b>	<b>0.78</b>	<b>(27.40)</b>	<b>19.72</b>	<b>(24.42)</b>
8	<b>Other comprehensive income</b>						
A	(i) Item that will not be reclassified to profit or loss	0.13	0.14	(0.19)	0.40	(0.58)	0.52
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.03)	(0.04)	0.05	(0.10)	0.15	(0.13)
B	(i) Item that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Other comprehensive income for the period (net of tax)</b>	<b>0.10</b>	<b>0.10</b>	<b>(0.14)</b>	<b>0.30</b>	<b>(0.43)</b>	<b>0.39</b>
9	<b>Total comprehensive (loss)/income for the period (7+8)</b>	<b>(32.79)</b>	<b>(6.36)</b>	<b>0.64</b>	<b>(27.11)</b>	<b>19.29</b>	<b>(24.03)</b>
10	<b>Earning per share of Rs. 10 each</b>						
	- Basic and diluted (in rupees) (not annualized)	(3.29)	(0.65)	0.08	(2.74)	1.97	(2.44)
11	<b>Paid-up equity share capital</b> (Face value of share - Rs 10 each)	100.00	100.00	100.00	100.00	100.00	100.00
12	<b>Other equity</b>						1,828.59
	See accompanying notes to the unaudited standalone financial results						

**SAURABH GOYAL**  
Digitally signed by SAURABH GOYAL  
Date: 2025.01.24  
18:07:25 +05'30'

NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009  
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900. CIN L24304MH2016PLC320868

**NURECA LIMITED**

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India  
Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com  
Corporate Identification Number: L24304MH2016PLC320868

**Notes to the Unaudited standalone financial results:**

- 1 The above unaudited standalone financial results for the quarter and nine months ended 31 December 2024 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 24 January 2025. The Limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website [www.nureca.com](http://www.nureca.com) and financials results at corporate section at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)
- 2 The business of the Company falls within single line of business i.e. business of home healthcare and wellness products. Accordingly, the segment related disclosures as per IND AS 108 are not applicable to the company.

*For and on behalf of Board of Directors of*

**Nureca Limited**

**SAURABH GOYAL** Digitally signed by  
SAURABH GOYAL  
Date: 2025.01.24  
18:07:34 +05'30'

**Saurabh Goyal**

(Managing Director)

DIN - 00136037

Place Muscat

Date: 24 January 2025

**NURECA LIMITED**

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009  
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,  
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

NURECA LIMITED							
Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868							
(Amount in INR million, unless otherwise stated)							
Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended 31 December 2024							
	Particulars	Quarter ended			Nine Months ended		Year ended
		31 December 2024 (Unaudited)	30 September 2024 (Unaudited)	31 December 2023 (Unaudited)	31 December 2024 (Unaudited)	31 December 2023 (Unaudited)	31 March 2024 (Audited)
1	Revenue from operations	264.63	311.89	223.74	779.21	749.58	919.28
2	Other income	14.77	31.71	59.01	104.42	117.73	105.14
3	<b>Total income (1+2)</b>	<b>279.40</b>	<b>343.60</b>	<b>282.75</b>	<b>883.63</b>	<b>867.31</b>	<b>1,024.42</b>
4	<b>Expenses</b>						
	Cost of material consumed	39.95	23.97	43.96	74.36	87.14	97.60
	Purchase of stock-in-trade	143.15	129.22	49.46	385.17	389.66	464.70
	Changes in inventories of stock-in-trade and finished goods	(17.79)	49.57	65.37	30.88	17.54	43.85
	Employee benefits expense	38.44	36.28	32.79	110.37	91.33	122.01
	Finance costs	1.75	2.69	1.10	5.94	3.10	4.89
	Depreciation and amortization expense	5.40	6.20	5.91	18.16	17.62	23.62
	Other expenses	101.02	96.42	74.71	265.83	221.64	293.19
	<b>Total expenses</b>	<b>311.92</b>	<b>344.35</b>	<b>273.30</b>	<b>890.71</b>	<b>828.03</b>	<b>1,049.86</b>
5	<b>Profit/(Loss) before income tax (3-4)</b>	<b>(32.52)</b>	<b>(0.75)</b>	<b>9.45</b>	<b>(7.08)</b>	<b>39.28</b>	<b>(25.44)</b>
6	<b>Tax expense</b>						
	- Current tax	(1.99)	5.75	12.32	11.17	15.52	15.60
	- Deferred tax charge/(credit)	(2.52)	(1.68)	(4.52)	(2.04)	0.24	(23.10)
7	<b>Profit/(Loss) after income tax (5-6)</b>	<b>(28.01)</b>	<b>(4.82)</b>	<b>1.65</b>	<b>(16.21)</b>	<b>23.52</b>	<b>(17.94)</b>
8	<b>Other comprehensive income</b>						
A	(i) Item that will not be reclassified to profit or loss	0.13	0.14	(0.19)	0.40	(0.58)	0.35
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.03)	(0.04)	0.05	(0.10)	0.15	(0.10)
B	(i) Item that will be reclassified to profit or loss	(0.06)	(0.02)	-	(0.08)	(0.02)	(0.03)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Other comprehensive income for the period (net of tax)</b>	<b>0.04</b>	<b>0.08</b>	<b>(0.14)</b>	<b>0.22</b>	<b>(0.45)</b>	<b>0.22</b>
9	<b>Total comprehensive income/(loss) for the period (7+8)</b>	<b>(27.97)</b>	<b>(4.74)</b>	<b>1.51</b>	<b>(15.99)</b>	<b>23.07</b>	<b>(17.72)</b>
10	<b>Earning per share of Rs. 10 each</b> - Basic and diluted (in rupees) (not annualized)	<b>(2.80)</b>	<b>(0.48)</b>	<b>0.16</b>	<b>(1.62)</b>	<b>2.35</b>	<b>(1.79)</b>
11	<b>Paid-up equity share capital</b> (Face value of share - Rs.10 each)	100.00	100.00	100.00	100.00	100.00	100.00
12	<b>Other equity</b>						1,831.11
	See accompanying notes to the unaudited consolidated financial results						

**SAURAB** Digitally signed by  
SAURABH GOYAL  
**H GOYAL** Date: 2025.01.24  
18:07:44 +05'30'

## NURECA LIMITED

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009  
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,  
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900 CIN L24304MH2016PLC320868

**NURECA LIMITED**

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India  
Tel: +91 -172-5292900, E-mail: [cs@nureca.com](mailto:cs@nureca.com), Website: [www.nureca.com](http://www.nureca.com)  
Corporate Identification Number: L24304MH2016PLC320868

**Notes to the unaudited consolidated financial results:**

- 1 The above unaudited consolidated financial results for the quarter and nine months ended 31 December 2024 as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 24 January 2025. The Limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website [www.nureca.com](http://www.nureca.com) and financials results at corporate section at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).
- 2 The business of the Group falls within single line of business i.e. business of home healthcare and wellness products. Accordingly, the segment related disclosures as per IND AS 108 are not applicable to the group.
- 3 The unaudited consolidated financial results include the financials results of the Parent company and its subsidiaries (collectively referred as 'the Group') as below.


**Parent Company**

Nureca Limited - Incorporated in India

**Subsidiaries**

- i) Nureca Technologies Private Limited
- ii) Nureca Healthcare Private Limited
- iii) Nureca Inc. USA

*For and on behalf of Board of Directors of  
Nureca Limited*

SAURABH  
GOYAL  
  
Saurabh Goyal  
(Managing Director)  
DIN 00136037

Place: Muscat  
Date: 24 January 2025

**NURECA LIMITED**

Correspondence Office : SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh 160009  
Registered Office : 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East,  
Mumbai City Maharashtra - 400063

Phone No. +91-172-5292900. CIN L24304MH2016PLC320868

**Limited Review Report on unaudited standalone financial results of Nureca Limited for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors of Nureca Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Nureca Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248WW-100022

**Ankush  
Goel**

Digitally signed  
by Ankush Goel  
Date: 2025.01.24  
16:38:18 +05'30'

**Ankush Goel**

Partner

New Delhi

24 January 2025

Membership No.: 505121

UDIN:25505121BMLCOC5583

Registered Office

**Limited Review Report on unaudited consolidated financial results of Nureca Limited for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors of Nureca Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Nureca Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of entities mentioned in Annexure I to this report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of one Subsidiary included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 65.81 million and Rs. 170.95 million, total net profit after tax (before consolidation adjustments) of Rs. 3.99 million and Rs. 10.38 million and total comprehensive income (before consolidation adjustments) of Rs. 3.99 million and Rs. 10.38 million, for the quarter ended 31 December 2024 and for the period from 1 April 2024 to 31 December 2024 respectively, as considered in the Statement. This interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Registered Office

**Limited Review Report (Continued)**

**Nureca Limited**

Our conclusion is not modified in respect of this matter.

7. The Statement includes the financial information of two Subsidiaries which have not been reviewed, whose financial information reflect total revenues (before consolidation adjustments) of Rs. Nil and Rs. Nil, total net profit / (loss) after tax (before consolidation adjustments) of Rs. 0.25 million and Rs. (0.31) million and total comprehensive income/ (loss) (before consolidation adjustments) of Rs. 0.25 million and Rs (0.31) million, for the quarter ended 31 December 2024 and for the period from 1 April 2024 and 31 December 2024 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, this interim financial information is not material to the Group.

Our conclusion is not modified in respect of this matter.

**For B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022

**Ankush  
Goel**

Digitally signed  
by Ankush Goel  
Date: 2025.01.24  
16:38:54 +05'30'

**Ankush Goel**

*Partner*

Membership No.: 505121

UDIN:25505121BMLCOD9270

New Delhi

24 January 2025



Limited Review Report (Continued)

Nureca Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Nureca Limited	Holding Company (incorporated in India)
2	Nureca INC	Subsidiary Company (incorporated in USA)
3	Nureca Healthcare Private Limited	Subsidiary Company (incorporated in India)
4	Nureca Technologies Private Limited	Subsidiary Company (incorporated in India)

- B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement, etc.**

—Not Applicable—

- C. Format for disclosing outstanding default on loans and debt securities**

There is no default on loans and debt securities during the quarter ended December 31, 2024.

- D. Format for disclosure of Related Party Transactions (applicable only for half-yearly filings i.e. 2<sup>nd</sup> and 4<sup>th</sup> quarter)**

—Not Applicable—

- E. Statement on impact of Audit qualifications (for audit report with modified opinion) submitted alongwith annual audited financial results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e. 4<sup>th</sup> quarter)**

—Not Applicable—